ライフサイエンスコーパス: dysmenorrhea

1 rual syndrome, heavy menstrual bleeding, and dysmenorrhea.

2 been adequately characterized in women with dysmenorrhea.

3 ld female who presented with infertility and dysmenorrhea.

4 .11 cm [95% CI, -0.50 to 0.29 cm]; P = .60), dysmenorrhea (-0.09 cm [95% CI, -0.49 to 0.30 cm]; P = .

5 t there was an association between FGM/C and dysmenorrhea (7,349 FGM/C and 4,411 non-FGM/C participan

6 usually turn to their PCP for evaluation of dysmenorrhea and CPP.

7 ale who presented with a one-year history of dysmenorrhea and cyclic pelvic pain.

8 entify genetic variants associated with both dysmenorrhea and depression, followed by colocalization

9 h was applied to determine causality between dysmenorrhea and depression.

10 ggests that depression significantly affects dysmenorrhea and identifies key genes and proteins invol

11 2 was a 14-year-old girl who presented with dysmenorrhea and lower abdominal pain since a few months

12 ss of diagnosis, reported moderate to severe dysmenorrhea and non-cyclical pelvic pain.

13 oses of elagolix were effective in improving dysmenorrhea and nonmenstrual pelvic pain during a 6-mon

14 The responses with respect to dysmenorrhea and nonmenstrual pelvic pain were sustained

15 HWW syndrome presenting with regular menses, dysmenorrhea and painful lump in hypogastric region on t

16 ic, estrogen-dependent condition that causes dysmenorrhea and pelvic pain.

17 n for depression among women presenting with dysmenorrhea and suggest new targeted preventive strateg

18 who had a clinical response with respect to dysmenorrhea and the proportion who had a clinical respo

19 manage, and refer as needed adolescents with dysmenorrhea and/or chronic pelvic pain (CPP) who are su

20 rning the 3 types of pain (noncyclical pain, dysmenorrhea, and dyspareunia) were analyzed separately

21 The most common presentation is pain and dysmenorrhea, and pain and abdominal mass in the lower a

22 s to explore the link between depression and dysmenorrhea by using an integrated and innovative appro

23 onnaire and visual analogue scales (VAS) for dysmenorrhea, chronic pelvic pain, and deep dyspareunia

24 Secondary outcomes were deep dyspareunia, dysmenorrhea, dyschezia, and back pain at follow-up.

25 re potential embryo transfer, with worsening dysmenorrhea, dyspareunia, and overall pelvic pain.

26 LUNA did not result in improvements in pain, dysmenorrhea, dyspareunia, or quality of life compared w

27 Menstrual pain, also known as dysmenorrhea, is a leading risk factor for bladder pain

28 sis, menorrhagia, polycystic ovary syndrome, dysmenorrhea, leiomyoma, and postpartum initiation.

29 endometriosis report pelvic pain, including dysmenorrhea, nonmenstrual pelvic pain, and dyspareunia,

30 a significant causal effect of depression on dysmenorrhea ['odds ratio' (95% confidence interval) = 1

31 ence was found to support a causal effect of dysmenorrhea on depression (P = .74).

32 Primary dysmenorrhea (PDM), a significant public health problem

33 effect on blood pressure, weight management, dysmenorrhea, postoperative nausea, and chemotherapy-ind

34 who had a clinical response with respect to dysmenorrhea was 46.4% in the lower-dose elagolix group

35 ation site reactions, breast discomfort, and dysmenorrhea were significantly more common in the patch